AdvanCell

AdvanCell is a biotech company in Sydney, Australia, founded in 2019. It has raised $427.0M across 3 rounds, most recently a $315.0M Venture Round in July 2026.

Changing the Course of Cancer Treatment

Headquarters
Sydney
Employees
11–50
Founded
2019
Business Model
B2B
Total Funding
$427.0M
Last Round
$315.0M Venture RoundJul 2026
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 1 investor for this company. The full record is or through the API.

About

AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer using lead-212 (212Pb). Headquartered in Sydney, Australia with a growing US presence, the company operates a vertically integrated platform for manufacturing and delivering 212Pb-based therapies, with a lead program targeting PSMA for prostate cancer.

Summary

It lists 11–50 employees. It has raised $427.0M in total across 3 rounds, most recently a $315.0M Venture Round in Jul 2026. Investors include Morningside Group.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Venture RoundGrowth RoundJul 2026
$315.0M

Sign up to see all 3 events

Funding: Series B through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

AdvanCell on Indexed.vc
<a href="https://indexed.vc/companies/advancel"><img src="https://indexed.vc/api/badge/company/advancel" alt="AdvanCell on Indexed.vc" width="260" height="76" /></a>